Onyx Pharma – ONXX – Bull of the Day
Source: http://www.zacks.com/commentary/11615/Onyx+Pharma+-+ONXX+-+Bull+of+the+DayPosted on Monday, July 27th, 2009 | In Market Commentary, Stocks to Watch
We maintain our Buy rating on Onyx (ONXX) shares with price target of $45.
Onyx delivered strong financial performance in 1Q09 and we expect the company will continue to deliver very good financials for 2009. Nexavar sales continued to grow in 1Q08, which was mainly attributed to the market penetration in liver cancer while market share has stabilized in kidney cancer market in spite of heavy competition. Total Nexavar sales came in at $178.1 million, up 17% year over year. This increase was mainly driven by international sales which reached $130 million, up 29% year over year.
EU and the US approved Nexavar for 1st line treatment of liver cancer in 4Q07. In Asia, South Korea and China have approved Nexavar for liver cancer. Other international filing is underway. We believe Nexavar
sales will be further boosted in 2009 and beyond due to this new indication.
Label expansion for Nexavar into other cancer indications such as breast cancer is under way. We believe Nexavar has a potential to become a blockbuster. We model sales of Nexavar will reach $1.1 billion in
2010.
The current price is attractive and we recommend investor to buy its shares at current level.
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Asia, Breast Cancer, cancer, China, Commission of European Communities;, kidney cancer, Liver Cancer, Market Commentary, Nexavar, south korea, Stocks to Watch, treatment of liver cancer;, United States, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.